The APOBEC3A Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the APOBEC3A gene in the TE1 human esophageal squamous cell carcinoma line. This product provides a heterogeneous loss-of-function model for studying APOBEC3A biology without the constraints of clonal selection.
The TE1 cell line, derived from a human esophageal squamous cell carcinoma, serves as a well-established in vitro model for ESCC, retaining key malignant properties such as unregulated proliferation, migration, and invasion. It is widely utilized to investigate ESCC pathogenesis, therapeutic resistance, and tumor progression.
APOBEC3A encodes a single-stranded DNA cytidine deaminase that deaminates cytosine to uracil, generating C-to-U lesions that can lead to C-to-T transitions if repaired incorrectly or replicated. This activity underpins both antiviral innate immunity, by hypermutating viral genomes, and cancer mutagenesis, contributing to APOBEC mutational signatures. Transcription of APOBEC3A is strongly induced by type I interferons (IFN-?? and IFN-??) through the interferon receptor and JAK kinases, which phosphorylate STAT1 and STAT2; these, along with IRF9, form the ISGF3 complex to drive expression. Additional upstream regulators include NF-??B and IL-27. APOBEC3A targets single-stranded DNA via interaction with replication protein A (RPA), and uracil excision by uracil DNA glycosylase (UNG) creates abasic sites that can cause DNA strand breaks. These breaks activate the DNA damage kinases ATM and ATR, leading to phosphorylation of Chk1, Chk2, and stabilization of p53, which promotes apoptosis. Thus, APOBEC3A connects inflammatory cytokine signaling to DNA damage and cell death pathways.
In the TE1 context, ablating APOBEC3A removes a primary source of endogenous mutagenesis, enabling researchers to assess how loss of APOBEC-mediated deamination affects mutational burden, genomic stability, and response to genotoxic insults. This model is invaluable for investigating the role of APOBEC signatures in ESCC progression and for evaluating whether APOBEC3A deficiency sensitizes cells to commonly used chemotherapeutics such as cisplatin, or alters invasive potential.
Typical applications include confirmation of knockout by Western blot or RT-qPCR, mutation analysis via whole-exome sequencing, DNA damage monitoring through ??-H2AX foci, clonogenic survival assays, drug sensitivity testing, and functional assessments of migration and invasion using standard assays. Flow cytometry can further probe cell cycle distributions and apoptosis. These polyclonal knockout cells thus support a wide range of investigations into cancer mutagenesis, antiviral innate immunity, and DNA damage signaling. For additional information, please contact Ascent Research.
